Relay Therapeutics is trading at $16.00, down 7.83% in pre-market, with no clear company-specific announcement identified to explain the decline. - The shares compare with an October 13 close of $17.36; no clear company-specific announcement dated October 14 was found, and the press-release page showed no new release in available results. - A Form 144 filed October 6 proposed a sale of 93,153 shares by officer Thomas Catinazzo; this is earlier context, not a confirmed explanation for the move. - Major indexes were mixed, without a broad market drop of comparable magnitude.